DSGN

9.0203.22%
JD

Justin D. Gover

Independent Director

Mr. Justin D. Gover, BSc, MBA, is Director of Design Therapeutics, Inc. from September 10, 2025. Mr. Gover served as Director at COMPASS Pathways plc since July 29, 2025 and serves as its Independent Director since 2025. Mr. Gover has years of leadership in the biopharmaceutical industry. He had been the Chief Executive Officer of GW Pharmaceuticals PLC since January 1999. He serves as Director of Aeovian Pharmaceuticals, Inc. since March 2024. He is Independent Director at Xenon Pharmaceuticals Inc. since August 2023. As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the GW Pharmaceuticals’s operations, as well as leading equity financings, strategy and business development activities. In 2001, he led the GW Pharmaceuticals’s initial public offering on the AIM stock exchange in London and in 2013 led the GW Pharmaceuticals ’s initial public offering in the U.S. on Nasdaq. He serves on the Board of CURE Epilepsy, Rady Children’s Institute for Genomic Medicine. Mr. Gover has experience in the pharmaceutical industry. Mr. Gover served as Managing Director of Gw Pharmaceuticals Plc at GW Research Ltd. He served as Managing Director at GW Pharmaceuticals PLC since January 1999. He served as the Head of Corporate Affairs at Ethical Holdings plc (now Amarin Corporation plc), where he was responsible for its strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. He served an Executive Director at GW Pharmaceuticals PLC since 1999 until May 5, 2021. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.

Positions